DORIS OBAZE: Open Payments
NPI 1457729287 · SUGAR LAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,416 in 20 payments from 11 companies in 2025. Trend: 2023 $611 · 2024 $853 · 2025 $1,416
Food & beverage: $1,416
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 4 | $240 |
| Gilead Sciences, Inc. | 2 | $209 |
| Amgen Inc. | 3 | $159 |
| Abbott Laboratories | 1 | $146 |
| AstraZeneca Pharmaceuticals LP | 1 | $134 |
| Xeris Pharmaceuticals, Inc. | 2 | $129 |
| ABIOMED | 1 | $126 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $96 |
| Eisai Inc. | 1 | $84 |
| Exact Sciences Corporation | 3 | $68 |
Products named: Korlym, PROCLAIM, AIRSUPRA, Livdelzi, RECORLEV, JOURNAVX, Epclusa, Leqembi.
Industry payments across TX — which companies pay providers there.
